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Abstract
In sub-Saharan Africa, more than 60% of all adults living with HIV in 2018 were women, 
according to the Joint United Nations Programme on HIV and AIDS (https://aidsinfo.unaids.org).
Largely as a result of early access to HIV testing and antiretroviral treatment (ART) at 
antenatal clinics, women were the first to benefit from “Treat All” approaches to ART; with 
the introduction of Option B+ policies starting in 2011, all pregnant and breast-feeding 
women were offered immediate ART initiation and life-long treatment, regardless of their 
CD4+ T-cell count or clinical staging. Women accounted for 67% of the 13.5 million adults 
receiving ART at the end of fiscal year 2018 in programs supported by the President’s 
Emergency Plan for AIDS Relief (PEPFAR) globally (www.pepfar.gov).
Providing the best available ART regimens to women requires complex decision making 
related to their childbearing potential, including weighing women’s health needs and 
experiences with medications, along with possible safety concerns for infants exposed to 
HIV medications during any current or future pregnancy. When a potential association with 
neural-tube defects (NTDs) in infants born to women receiving dolutegravir (DTG)-based 
ART was identified in May 2018, the risks of possible adverse outcomes for infants exposed 
to DTG became a major focus of HIV policy discussions.1 Yet such discussions should 
include consideration of all the risks, including those for women who might receive inferior 
ART regimens, if we are to ensure the best achievable access to treatment options and 
improved health outcomes for women living with HIV.
Before May 2018, global HIV programs were poised to transition the preferred first-line 
ART regimen rapidly from tenofovir, lamivudine, and efavirenz to tenofovir, lamivudine, 
and DTG, which poses a lower risk of treatment failure and causes rapid viral suppression.
2,3
 The momentum behind this shift waned, however, after the release of interim World 
Health Organization (WHO) guidance in July 2018 that included a note of caution advising 
that adolescent girls and women of child-bearing potential be given a DTG-based regimen 
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only if it was used in tandem with a consistent and reliable form of contraception; other 
regulatory bodies followed with similar statements of caution. Despite the release of more 
permissive WHO guidance in December 2018, the response to the NTD safety signal has 
varied among countries, with a limited number allowing women to make an informed 
decision, some providing access to the regimen only for patients using contraception, and 
others not offering access to DTG-based regimens for any women of childbearing potential.
Policy discussions have focused primarily on the possible increased risk of having a child 
with an NTD — largely overlooking the importance of shared decision making between a 
woman and her health care provider and the possible risks of adverse out-comes for pregnant 
women who might receive inferior ART regimens and their infants. When global 
policymakers and national HIV programs make recommendations that restrict women’s 
access to medications on the basis of uncertain — or even known — safety concerns related 
to childbearing potential, women’s ability to make their own decisions about treatment 
options that best fit their life circumstances and beliefs is severely limited. By contrast, 
nondirective counseling is a key strategy for ensuring that women are empowered to 
participate in their own health care decisions. Health care providers taking this approach lay 
out information and clearly describe all the risks as they are currently known, along with 
options for avoiding or mitigating these risks.
Respecting the autonomy of women to participate actively in their own health care decision 
making promotes adherence to treatment regimens. Such participation is especially 
important for decisions regarding lifelong HIV treatment, since adherence is critical to 
averting development of drug-resistant HIV strains and maintaining viral suppression. In 
addition, it’s important that discussions of a woman’s intentions regarding pregnancy occur 
before conception, because most pregnancies are not recognized until after the critical 
window for development of major organs and structures, such as the neural tube. Early 
conversations about pregnancy intentions can avert unnecessary changes in ART regimens 
during pregnancy that might increase the risks of adverse health outcomes for the mother 
and infant (e.g., reduced HIV viral suppression, with resulting increased risks of 
complications and death, and a potentially higher risk of mother-to-child HIV transmission), 
without conferring benefit to either one.
Treatment decision making related to future and current pregnancies is complicated by the 
lack of data on medication safety during pregnancy. Despite the common use of prescription 
medications in pregnancy, a review of 172 medications approved by the Food and Drug 
Administration between 2000 and 2010 showed that only 4 (2%) of these medications had 
data on teratogenic risk in humans.4 Clinical trials examining drug efficacy and safety 
routinely exclude pregnant and breast-feeding women, thereby contributing to the dearth of 
evidence on which to base treatment decisions. Moreover, even if participation of pregnant 
women were increased, premarketing clinical trials often include relatively small numbers of 
people and so are unlikely to have sufficient statistical power to detect rare outcomes, such 
as birth defects, especially if a drug’s teratogenic potential is low.5
Collection of postmarketing data through pregnancy registries and birth-defects surveillance 
is therefore essential. Pregnancy registries are typically designed to monitor the safety of a 
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particular drug or class of drugs for a specific indication; one example is the Antiretroviral 
Pregnancy Registry, which monitors exposures to HIV medications, relying on HIV clinical 
providers to voluntarily submit reports. Unfortunately, there is a paucity of systems for 
monitoring birth defects in much of the world. This gap, compounded by factors such as 
limited population exposure to a new teratogen, the heterogeneity of causes of birth defects, 
and difficulties in maintaining enrollment in prospective systems, continues to limit our 
capacity to rapidly detect teratogenic risk. Attention to critical knowledge gaps about risks 
associated with use of medications in pregnancy and enhancement of existing systems for 
identifying these risks are key public health priorities, especially given the certainty that 
additional safety signals will emerge as new medications enter the market.
Our knowledge about the relation between periconceptional use of DTG-based ART and 
NTD risk will advance and be refined as new data continue to become available (see the 
article by Zash et al. and the letter to the Editor by Raesima et al., available at NEJM.org). 
Similar early safety signals seen with another HIV medication, efavirenz, and with the 
anticonvulsant lamotrigine were not borne out by additional data, and these medications are 
now considered safer alternatives than others used for HIV and epilepsy, respectively, in 
women who are or might become pregnant. These experiences highlight an inherent tension 
in policy decisions: the desire to react quickly in order to avoid one poor outcome may result 
in another, unintended negative outcome. If the current suspected association between DTG 
and NTDs turns out not to exist, or continues to weaken, the delays that have occurred in 
global expansion of DTG-based treatment since the safety signal was reported in mid-2018 
will represent missed opportunities for improving global and individual health.
At home and abroad, achieving and maintaining control of the HIV epidemic will require 
sustained viral suppression, and moving to improved regimens is important for reaching this 
goal. We believe that global HIV programs have an imperative to provide the option to 
choose DTG-based regimens — which have been shown to achieve superior outcomes — to 
all people living with HIV, regardless of their sex or childbearing intentions. Enhanced 
attention to the needs of HIV-positive women of childbearing potential must be part of the 
epidemic-control strategy; this includes ensuring that women’s autonomy is respected, that 
their pregnancy intentions are known and supported, and that systems are in place to monitor 
the safety of drugs for women and infants during clinical trials and after approval for 
widespread use.
In this period of uncertainty regarding the potential NTD risk conferred by DTG-based 
regimens, women’s autonomy to make their own health-related decisions must remain a 
central tenet of public health programs. Public health leaders can ensure that global guidance 
considers all risks related to DTG, including those associated with receiving inferior 
regimens, and that women receive all the information they need to make their own, informed 
choices about treatment.
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